Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 1Rhabdoid Tumor 1Glioblastoma 1Colorectal Neoplasms 1Chordoma 1Advanced Rare Malignant Solid Neoplasm 1

Interventions

Doxorubicin 20Cyclophosphamide 18Radiotherapy 17Ifosfamide 13Vincristine 12Magnetic Resonance Spectroscopy 12Specimen Handling 11Biopsy 10Etoposide 9Filgrastim 8Dactinomycin 8X-Rays 6Temozolomide 6Sirolimus 6Phantoms, Imaging 6Melphalan 6temsirolimus 5cixutumumab 5Thalidomide 5Celecoxib 5Sorafenib 4Radiation 4Nuclear Medicine Department, Hospital 4Ipilimumab 4Fluorodeoxyglucose F18 4Chemotherapy, Adjuvant 4Carboplatin 4pazopanib 3ixabepilone 3cabozantinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sarcoma × Tiragolumab × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡